Subject: POT STOCKS .. Review ..FROM AUSTRALIA RESEARCH .. MORNINGSTAR

 

 

 

5 pot stocks join Australia Morningstar coverage list Kristoffer Inton  |  11 Jul 2019 

 

 

 

We have initiated coverage of cannabis, an industry we forecast to grow by nine times through 2030 amid widening legalization and increased participation for the US, Canadian, and international markets.

 

 

 

For the United States, recreational cannabis and medicinal cannabis have penetrated just 8 per cent and 21 per cent of their estimated markets, leading to our expectation for 25 per cent and 15 per cent compound annual growth rates through 2030, respectively. We expect six more states to legalize recreational cannabis and three states to expand commercial distribution. Furthermore, we expect the federal government will recognize states’ rights to decide legality.

 

 

 

For Canada, despite recent recreational legalization, cannabis has penetrated just 12 per cent of our estimated market, setting the stage for a 20 per cent CAGR through 2030. However, increasing competition from other countries could limit the opportunity for Canadian producers to US$20 billion.

 

 

 

For the international market (which excludes Canada and the United States), we forecast market potential of nearly US$43 billion and a 23 per cent CAGR through 2030 as more countries recognize the benefits of medical cannabis.

 

 

 

Of the five cannabis companies we now cover--  Aurora Cannabis (XNYS: ACB),  Canopy Growth (XNYS: CGC)/(XTSE: WEED),  Cronos (XNAS: CRON),  Curaleaf (PINX: CURLF)/(XCNQ: CURA), and  Tilray (XNAS: TLRY)--we think Aurora, Canopy, and Curaleaf offer investors attractive risk-adjusted upside at current prices.

 

 

 

We assign all companies a no-moat rating and stable moat trend rating, as they will struggle to earn economic profit as they spend on growth in this early-stage industry.

 

 

 

Aurora Cannabis

 

Ticker ACB

 

 

 

 

 

 

 

Last close US$7.39

 

 

 

Fair value US$10

 

 

 

Value 27 per cent discount

 

 

 

Moat None

 

 

 

Data as of July 11, 2019

 

 

 

Aurora Cannabis cultivates and sells cannabis in Canada and exports medical cannabis internationally. Our fair value estimates are US$10 and C$13 per share. Our valuation is based on a 10-year explicit forecast that assumes a roughly 41 per cent volume CAGR, about a 2 per cent price CAGR, and a 2028 operating margin before plant adjustments of 35 per cent.

 

 

 

Aurora is focused on becoming a large-scale, low-cost producer by expanding and optimizing its cultivation operations. Unlike its Canadian peers, Aurora has yet to enter a strategic partnership with a major alcohol, tobacco, or pharmaceutical company. It also does not offer investors any US exposure.

 

 

 

Canopy Growth

 

Ticker CGC

 

 

 

Last close US$38.60

 

 

 

Fair value US$54

 

 

 

Value 28 per cent discount

 

 

 

Moat None

 

 

 

Data as of July 11, 2019

 

 

 

Canopy Growth grows and sells cannabis in Canada and, to a lesser extent, global markets. Our fair value estimates are US$54 and C$71 per share. Our valuation is based on a 10-year explicit forecast that assumes a 30 per cent volume CAGR, a 4 per cent price CAGR, and a 2029 operating margin before plant adjustments of 37 per cent.

 

 

 

Canopy offers two unique advantages. First, it will acquire US-based Acreage Holdings, a cannabis company with vertically-integrated operations in 20 states, for US$3.4 billion immediately upon a change to federal law, giving it entry into the largest and most attractive cannabis market. Second, a strategic investment from Constellation Brands can help Canopy develop cannabis-infused consumer products.

 

 

 

Cronos Group

 

Ticker CRON

 

 

 

Last close US$15.29

 

 

 

Fair value US$11

 

 

 

Value 41 per cent premium

 

 

 

Moat None

 

 

 

Data as of July 11, 2019

 

 

 

Cronos Group cultivates and sells cannabis predominantly in Canada and, to a lesser extent, global markets.

 

 

 

Our fair value estimates are US$11 and C$14.50 per share. Our model uses a 10-year explicit forecast that assumes a roughly 31 per cent volume CAGR, a 3 per cent price CAGR, and a 2028 operating margin before plant adjustments of 35 per cent.

 

 

 

Cronos is expanding its capacity with plans to cultivate in Israel, Colombia, and Australia through joint ventures. Cronos also has limited US exposure through a research and development partnership with Ginkgo Bioworks to produce cultured cannabinoids.

 

 

 

In addition, Altria Group’s investment provides Cronos with an experienced partner to navigate strict regulatory environments.

 

 

 

Curaleaf Holdings

 

Ticker TLRY

 

 

 

Last close US$6.86

 

 

 

Fair value US$10.50

 

 

 

Value 35 per cent discount

 

 

 

Moat None

 

 

 

Data as of July 11, 2019

 

 

 

Curaleaf Holdings cultivates and sells cannabis in the US with a presence in 15 states. Our fair value estimates are US$10.50 and C$14 per share. Our valuation is based on a 10-year explicit forecast that assumes a roughly 36 per cent revenue CAGR, a 3 per cent price CAGR, and a 2028 operating margin before plant adjustments of 32 per cent.

 

 

 

Curaleaf offers the advantage of pure-play exposure to the US through a vertically integrated operation that includes cultivation, processing, and dispensary operations on the East and West Coasts. Unlike its Canadian peers, Curaleaf does not operate internationally, which is a disadvantage since the global market looks lucrative.

 

 

 

Tilray cultivates

 

Ticker TLRY

 

 

 

Last close US$45.93

 

 

 

Fair value US$40

 

 

 

Value fairly valued

 

 

 

Moat None

 

 

 

Data as of July 11, 2019

 

 

 

Tilray cultivates and sells cannabis in Canada and exports to 13 countries. Our fair value estimate is US$40 per share. Our valuation is based on a 10-year explicit forecast that assumes a roughly 24 per cent volume CAGR, a roughly 4 per cent price CAGR, and a 2028 operating margin before plant adjustments of 30 per cent.

 

 

 

Tilray has pursued options to improve its international and recreational competitiveness. It has expanded cultivation facilities to Portugal to supply European demand with cheaper production. A partnership with Anheuser-Busch InBev can help it create cannabis-infused drinks, while a partnership with Authentic Brands Group will help it market CBD products in the US.

 

 

 

Some advantages, but not enough for a moat

 

We don’t believe any of the cannabis companies we cover have an economic moat. Although there appear to be potential sources of competitive advantage through intangible assets and cost advantage, several barriers prevent the companies from earning a moat in the medium term.

 

 

 

Regulation intangible assets

 

 

 

We believe the most likely moat source would come from intangibles stemming from regulation. Cultivators and dispensaries require government licenses to operate in every market where recreational or medical cannabis is legal. As a result, companies with licenses could be protected from outside competition, helping establish pricing power. This could prove particularly true if holding an existing license provides an advantage for when new licenses are issued. History suggests this could be possible, as Illinois’ early plans for recreational legalization would hand an advantage to companies with medical cultivation and dispensary licenses. However, even if this were the case, we see sustained positive economic profits for cannabis companies as unlikely over the next 10 years.

 

 

 

Challenges to economic profit

 

 

 

Because the cannabis industry remains in the growth stage, we think that years of significant investment will be necessary. An extended capital expansion cycle through the next several years means that companies are unlikely to generate returns on invested capital in excess of their costs of capital.

 

 

 

Also, we see both governments and the black market squeezing cannabis cultivators and dispensaries and preventing economic profit generation. With national, state, and local governments reeling from budget problems, the emergence of cannabis as a legal product has come to be viewed as a funding panacea. For example, Washington state has implemented a 37 per cent tax rate on recreational cannabis - early evidence that governments, with full control over licensing, will attempt to maximize their economics.

 

 

 

All else equal, on the other end of the value chain, consumers would probably bear any government tax increase, as in the cigarette market. However, a large and accessible black market effectively serves as a price ceiling that consumers are willing to pay. When California legalized recreational cannabis with a relatively high tax, the legal market shrank as consumers moved back into the black market.

 

 

 

Companies that are involved in the cultivation and sale of cannabis have the least leverage against the government and consumers. Although there could be years of economic profit generation when supply has been slow to respond with expansions, we do not have confidence that cannabis companies could consistently earn economic profits over the next decade.

 

 

 

Brand intangible assets

 

Potentially offsetting the challenge of generating economic profit from regulation intangibles, we think that the creation of brand intangibles would help cannabis companies pass increased costs to consumers, thus protecting their own economic profit. Alcohol and cigarettes are typically highly taxed, but producers have established strong enough differentiation and brand intangibles that consumers are willing to pay premiums.

 

 

 

Although the cannabis companies are attempting to strengthen their brands, we see the creation of a brand intangible within the next decade as unlikely. Canadian regulation restricts packaging to be bare and unexciting and bars direct contact between the company and dispensary workers who provide expert advice and help consumers select their cannabis. Advertising is possible in venues in which only adults will be present, but we think limitations create meaningful barriers to brand creation. We believe that the selection process in Canada will be more like selecting wine than liquor, in which the choice is made on qualities rather than brand.

 

 

 

Restrictions are laxer in the US, where there are fewer limitations on packaging and direct contact with dispensaries is allowed. While brand power may strengthen eventually, we think it is highly unlikely that any brand will be strong enough in the next 10 years to command pricing power, and there are a few reasons for this:

 

 

 

Because we anticipate that federal legalization will take a few years, cultivation and selling is limited to intrastate. This limits any brand creation to a local level for the next several years.

 

Although a strong relationship with a dispensary worker could provide an advantage, we think these workers would be loyal to whichever company last paid them, requiring significant marketing expense to maintain relationships and eroding economic profit.

 

While typical consumer product companies, and even tobacco companies earlier in their history, have built brand recognition through advertising campaigns, we expect cannabis will face the same if not stricter limitations as tobacco in advertising in the US. We believe this makes it even harder for cannabis companies to build a recognizable brand, as opportunities to address the consumer will be limited.

 

 

 

Under the Family Smoking Prevention and Tobacco Control Act, tobacco product advertising faces restrictions on outdoor advertising near schools and playgrounds, sports and entertainment brand sponsorships, and point-of-sale advertising, among others. Advertising on television and radio has been banned since 1971 by the Federal Communications Commission. Although tobacco companies spend roughly US$10 billion in marketing in the US, roughly two thirds is spent on price discounts to reduce the cost of cigarettes to consumers. While this may help tobacco companies protect brand intangibles with its customers, we don’t think the same strategy could build a new brand intangible in cannabis.

 

 

 

As cannabis shifts from its traditional smoking form to infused drinks and food products, there may be potential for the creation of brand intangibles. However, we think the development and widespread distribution of regulator-approved infused products will take too long for a brand intangible to drive excess returns within the next decade.

 

 

 

Cost advantage

 

We think it is unlikely that the cannabis companies we cover will be able to establish a cost advantage. Because of the climate, most cannabis in Canada is grown either in greenhouses or indoors. Although this allows for higher-quality cannabis to be grown, these methods are also much higher cost because of the required lighting and climate control. Additionally, advantages in greenhouse and indoors can be much more easily imitated than geographic advantages that may be present in outdoor cultivation.

 

 

 

Cannabis grown in the Western US in states like Oregon is grown outdoors. Without the need for as much equipment, costs are significantly lower, partially offset by fewer harvests and lower quality. However, labour is the single-largest cost of production for any growing method. Thus, countries with cheaper labour that have expressed a desire to establish a medical cannabis industry are likely to produce at a lower cost than any US or Canadian cultivator.

 

 

 

Kristoffer Inton does not own shares in any of the securities mentioned above.

 

 

 

Kristoffer Inton is an Equity Analyst for Morningstar

 

…………………………

 

 

 

Lot more Reading here:

 

 

 

Read the latest

……………………………………….. ·         Cannabis stocks were hammered after CannTrust revealed a significant regulatory issue. ·         Health Canada revoked one license and issued seven new ones. ·         Ohio is looking into licensing issues for two MSOs. ·         The three 420 Investor model portfolios are up 17-40% in 2019. Review The market was under extreme pressure this week after CannTrust revealed that it used not-yet-licensed rooms for cannabis production. Its products are temporarily unavailable for sale, and the company is submitting responses to Health Canada by next week. It's not clear how the regulator will deal with the situation, which could include destruction of the inventory, a fine and possible loss or suspension of its license. Health Canada issued seven new licenses, boosting the total to 196. It also revoked the previously suspended license of Agrima (Ascent Industries). Ohio is reviewing licensing for Harvest and Acreage, continuing a trend of states pushing back against the efforts of MSOs to get multiple licenses under their control. During the week, I posted the second of three articles for the August edition of the 420 Investor Newsletter: Why HEXO Corp Deserves a Look Here are some of this week's highlights for Focus List names: ·         ACRGF CMO Harris Damashek left the company. ·         CTST revealed a major problem that threatens its long-term viability as well as its near-term financials. The company jumped the gun, cultivating in rooms, currently licensed, before approval by Health Canada. The company faces punishment that could range from fines, inventory destruction and possible license suspension or revocation. ·         CVSI resolved its five-year old lawsuit as the plaintiffs dropped their case related to the original acquisition of its assets. It announced more than 500 acres of U.S. hemp production for 2019. ·         FFLWF opened another Alberta store, its 23rd overall ·         GRWG added former Home Depot CEO Bob Nardelli as an advisor ·         GTBIF opened its fourth Florida dispensary ·         HEXO will be moving from the NYSE American to the NYSE on July 16th. ·         HRVSF announced an acquisition in Arizona and a dispensary opening in North Dakota.The Supreme Court of BC approved its combination with Verano Holdings. ·         IIPR announced a $19.8 million Michigan project with Ascend, its third in the state. The company sold 1.3 million shares at 126. ·         ITHUF announced that its CBD For Life products will be distributed by Dillard's. It's CFO bought 20K shares on the open market. ·         KSHB announced that it has applied to the NASDAQ for listing. The company's Q3 showed revenue slightly above expectations with EPS in line. ·         MMNFF renegotiated the terms on its $250 million debt deal with Gotham and sold them an additional $30 million of stock at US$2.37. It began selling smokable flower in Florida. ·         OGI announced that it has developed a proprietary nano-emulsification technology that will allow for the production of both liquid and powdered cannabinoid products. ·         SNNVF former President Pedersen revealed the sale of 792K shares since departing in May ·         SPRWF closed its Blissco acquisition ·         TCNNF launched SLANG Worldwide RESERVE vaporizer cartridges in Florida. The company extended voluntary lock-ups from July to January for a portion and next July for the majority of the 62.25 million shares representing 59% of the company's stock on a converted basis. ·         TLRY imported medical cannabis into Ireland for the first time ·         TRSSF received an amendment to its license that permits it to sell oils in Canada The Global Cannabis Stock Index fell for the second straight week, dropping 9.0% to 75.03: The index, up 17.2% so far in 2019, lost 54.9% in 2018 after gaining 91.8% in 2017 and 88.8% in 2016. It currently includes 64 stocks and ended 2018 at 64.02: Model Portfolios 420 Opportunity ended the week valued at $110,420, down 9.4%. The model portfolio has gained 16.7% year-to-date and has increased 121% since April 2014. 420 Quality ended the week at $145,227, down 8.8%, and has increased 22.0% year-to-date. This model portfolio was launched in March 2017 targeting long-term investors seeking to invest in leading cannabis stocks with low portfolio turnover and has gained 190.5% since inception compared to the 7.2% decrease in the index. Flying High ended the week valued at $226,206, down 7.3%. The year-to-date gain has been 40.2%, while the return since inception in late 2013 has been 2162%. Outlook The cannabis sector is seeing rapidly improving quality due to new entrants and some of the older names executing. Valuations generally remain cautionary, and fundamentals are questionable for most of the over 800 companies in the sector. While the sector has been volatile and has declined since early 2018, the longer-term trend since early 2016 has been bullish. There are some catalysts ahead, including the changes ahead due to hemp legalization, progress in the Canadian legalization that commenced October 17th and in German MMJ as well as the continued roll-out of the implementations in California and Massachusetts for adult-use as well as medical cannabis in several other states. The demise of the Cole Memo had left a big overhang in the U.S. market, but I believe this is now behind us and advocate a more aggressive approach for investors with respect to legitimate U.S. companies. A major change has been the stepped up pace at which higher quality U.S. operators are going public via the CSE in Canada. Consolidation within both Canada and the U.S. will continue, but the Canopy deal with Acreage paves the way for potentially more cross-border consolidation. Finally, expect to see more of the Canadian LPs list on major U.S. exchanges. The big themes ahead are likely to be continued cross-industry investment into the sector and more consolidation in Canada and in the U.S., insight into the President's plans regarding the federal view on state-legal cannabis (especially in light of the apparent deal with Senator Cory Gardner and the introduction in the Senate of Strengthening the Tenth Amendment Entrusting States (STATES) Act ), better clarity from the federal government for banks and cannabis research, FDA pushback towards the CBD from industrial hemp industry, the GW Pharma launch of Epidiolex, the inclusion of a broader range of extracts in Health Canada's ACMPR program and its continued growth in patient enrollment, the rollout of MMJ in Denmark, Germany, Mexico and in Australia as well as continued advances in South America, progress with respect to the new legal cannabis implementations in CA, IL, MA and MI, and the new MMJ implementations in Arkansas, Florida, Maryland, Michigan, Ohio, Oklahoma, Pennsylvania and Texas, possible legalization via the legislatures in CT, MD, MN, NH, NJ, NM, NY and RI and implementation of potential commercial programs in ME and VT. The 2020 elections will start to get a lot of attention later this year as well. Here are some of the most interesting stories we published on New Cannabis Ventures this week: Cannabis REIT IIPR Sells 1.3 Million Shares at $126 CannTrust Flagged by Health Canada for Cannabis Production from Previously Unlicensed Grow Rooms Demetrix Raises $50 Million to Pursue Cannabinoid Biosynthesis Former Home Depot CEO Bob Nardelli to Advise Hydroponics Retailer GrowGeneration Gotham Green to Invest Additional $30 Million Into Medmen After Revising Terms to Prior $250 Million Financing Green Growth Brands to Buy Cannabis Extracts Company Moxie for $310 Million iAnthus Subsidiary CBD For Life Continues to Expand National Footprint with Dillard’s Department Store Partnership KushCo Holdings Generates $41.5 Million in Revenue in Fiscal Q3 Trulieve Cannabis Corp. Announces Extension of Voluntary Lock-Up Agreements with Company Founders Resources: ·         Stay on top of all of the NCV news on publicly-traded stocks ·         Track cannabis stocks with the Global Cannabis Stock Index ·         Follow Canadian Producers with the Canadian Cannabis LP Index ·         Monitor the American Cannabis Operator Index ·         Access free Canadian cannabis investor resources ·         Learn about our featured companies ·         Check out our "Revenue Tracker" ·         Discover upcoming new issues and IPOs ·         Stay on top of upcoming earnings calls ·         Subscribe to the free Weekly Newsletter ·         Follow all the NCV news real-time, by liking the Facebook page ·         Get the NCV App (Apple) ·         Get the NCV App (Google Play) ·         Find a job with a leading cannabis company ·         Read my articles on the Forbes Contributor site ·         Read my articles on Leafly